Go Pro
→ Barricks gold output fell from 2 million ounces to 719000 (From Golden Portfolio) (Ad)tc pixel Free HBP Stock Alerts

Helix BioPharma (HBP) Competitors

Helix BioPharma logo
C$1.87 +0.07 (+3.89%)
As of 02:47 PM Eastern
Compare

HBP vs. PLI, ABCN, TH, BCT, and SCYB

Should you buy Helix BioPharma stock or one of its competitors? Helix BioPharma's main competitors and comparable companies include ProMetic Life Sciences (PLI), VIVO Cannabis (ABCN), Theratechnologies (TH), BriaCell Therapeutics (BCT), and Scythian Biosciences (SCYB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Helix BioPharma compare to ProMetic Life Sciences?

ProMetic Life Sciences (TSE:PLI) and Helix BioPharma (TSE:HBP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

0.0% of Helix BioPharma shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Helix BioPharma has lower revenue, but higher earnings than ProMetic Life Sciences. Helix BioPharma is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life SciencesC$39.91M0.00-C$1.47B-C$63.06N/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A

ProMetic Life Sciences' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
ProMetic Life SciencesN/A N/A N/A
Helix BioPharma N/A -21.54%-279.98%

In the previous week, Helix BioPharma had 2 more articles in the media than ProMetic Life Sciences. MarketBeat recorded 2 mentions for Helix BioPharma and 0 mentions for ProMetic Life Sciences. ProMetic Life Sciences' average media sentiment score of 0.00 equaled Helix BioPharma'saverage media sentiment score.

Company Overall Sentiment
ProMetic Life Sciences Neutral
Helix BioPharma Neutral

Summary

Helix BioPharma beats ProMetic Life Sciences on 5 of the 9 factors compared between the two stocks.

How does Helix BioPharma compare to VIVO Cannabis?

Helix BioPharma (TSE:HBP) and VIVO Cannabis (CVE:ABCN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

0.0% of Helix BioPharma shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

VIVO Cannabis' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
VIVO Cannabis N/A N/A N/A

In the previous week, Helix BioPharma had 2 more articles in the media than VIVO Cannabis. MarketBeat recorded 2 mentions for Helix BioPharma and 0 mentions for VIVO Cannabis. Helix BioPharma's average media sentiment score of 0.00 equaled VIVO Cannabis'average media sentiment score.

Company Overall Sentiment
Helix BioPharma Neutral
VIVO Cannabis Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
VIVO CannabisN/AN/AN/AN/AN/A

Summary

Helix BioPharma beats VIVO Cannabis on 3 of the 5 factors compared between the two stocks.

How does Helix BioPharma compare to Theratechnologies?

Helix BioPharma (TSE:HBP) and Theratechnologies (TSE:TH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

0.0% of Helix BioPharma shares are owned by institutional investors. Comparatively, 0.5% of Theratechnologies shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by company insiders. Comparatively, 1.2% of Theratechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Helix BioPharma has a beta of 0.433836, indicating that its stock price is 57% less volatile than the broader market. Comparatively, Theratechnologies has a beta of 0.256166, indicating that its stock price is 74% less volatile than the broader market.

In the previous week, Helix BioPharma had 2 more articles in the media than Theratechnologies. MarketBeat recorded 2 mentions for Helix BioPharma and 0 mentions for Theratechnologies. Helix BioPharma's average media sentiment score of 0.00 equaled Theratechnologies'average media sentiment score.

Company Overall Sentiment
Helix BioPharma Neutral
Theratechnologies Neutral

Helix BioPharma has a net margin of 0.00% compared to Theratechnologies' net margin of -11.81%. Theratechnologies' return on equity of 16.59% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
Theratechnologies -11.81%16.59%5.15%

Theratechnologies has higher revenue and earnings than Helix BioPharma. Helix BioPharma is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
TheratechnologiesC$84.38M2.44-C$1.96M-C$0.19N/A

Summary

Theratechnologies beats Helix BioPharma on 6 of the 11 factors compared between the two stocks.

How does Helix BioPharma compare to BriaCell Therapeutics?

BriaCell Therapeutics (CVE:BCT) and Helix BioPharma (TSE:HBP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

0.0% of Helix BioPharma shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BriaCell Therapeutics' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A N/A N/A
Helix BioPharma N/A -21.54%-279.98%

Helix BioPharma is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/AN/A-C$0.38N/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A

In the previous week, Helix BioPharma had 2 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 2 mentions for Helix BioPharma and 0 mentions for BriaCell Therapeutics. BriaCell Therapeutics' average media sentiment score of 0.00 equaled Helix BioPharma'saverage media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
Helix BioPharma Neutral

Summary

Helix BioPharma beats BriaCell Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Helix BioPharma compare to Scythian Biosciences?

Scythian Biosciences (CVE:SCYB) and Helix BioPharma (TSE:HBP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Scythian Biosciences' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Scythian BiosciencesN/A N/A N/A
Helix BioPharma N/A -21.54%-279.98%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scythian BiosciencesN/AN/AN/AN/AN/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A

In the previous week, Helix BioPharma had 2 more articles in the media than Scythian Biosciences. MarketBeat recorded 2 mentions for Helix BioPharma and 0 mentions for Scythian Biosciences. Scythian Biosciences' average media sentiment score of 0.00 equaled Helix BioPharma'saverage media sentiment score.

Company Overall Sentiment
Scythian Biosciences Neutral
Helix BioPharma Neutral

0.0% of Helix BioPharma shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Helix BioPharma beats Scythian Biosciences on 3 of the 5 factors compared between the two stocks.

Get Helix BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for HBP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HBP vs. The Competition

Export
MetricHelix BioPharmaBiotechnology IndustryHealthcare SectorTSE Exchange
Market CapC$142.83MC$3.74BC$7.06BC$12.54B
Dividend Yield1.50%3.69%2.57%6.20%
P/E Ratio-46.7510.67269.0630.69
Price / SalesN/A1,294.08602.439.75
Price / Cash11.32102.8870.4882.29
Price / Book9.7216.7812.914.60
Net Income-C$50.55M-C$13.32MC$3.45BC$299.09M
7 Day Performance16.88%1.74%1.12%0.94%
1 Month Performance29.86%1.60%1.79%3.90%
1 Year Performance53.28%56.43%67.69%36.05%

Helix BioPharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HBP
Helix BioPharma
N/AC$1.87
+3.9%		N/A+60.7%C$142.83MN/AN/A9
PLI
ProMetic Life Sciences
N/AN/AN/AN/AC$317.06MC$39.91MN/A487
ABCN
VIVO Cannabis
N/AC$1.32
+5.6%		N/A+0.0%C$256.62MN/AN/AN/A
TH
Theratechnologies
N/AC$4.47
-4.9%		N/A+0.2%C$205.53MC$84.38MN/A103
BCT
BriaCell Therapeutics
N/AC$10.60
-3.8%		N/A+0.0%C$168.68MN/AN/A5

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:HBP) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
AI insiders stockpile guns, gold & gas masks
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Who Really Gets Rich from IPOs?
Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...
Weiss Ratings | Sponsoredtc pixel
$100 for this… $500 for that. Here’s how to stop the bleeding today
Rising costs are squeezing households nationwide. USA Today reports more families are moving in together, whil...
Brownstone Research | Sponsoredtc pixel